---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Indication"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Indication. Topics: Proposed indication under FDA review: adults with obstructive sleep apnea; Intended disease severity range: mild, moderate, and severe; Phase 3 population: adults intolerant to or refusing PAP therapy. 3 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/indication"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Proposed indication under FDA review: adults with obstructive sleep apnea

> “filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea”

Source: [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109)

<a id="topic-2.1.2.5-2"></a>

### Intended disease severity range: mild, moderate, and severe

> “We are developing Oxnimbi with the intent for broad utilization across the spectrum of disease severity (mild, moderate and severe).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.5-3"></a>

### Phase 3 population: adults intolerant to or refusing PAP therapy

> “SynAIRgy enrolled adults with mild-to-severe OSA who were intolerant to or refused PAP therapy into a randomized, double-blind, placebo-controlled, 26-week parallel-arm trial of AD109 vs placebo across 69 centers.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “All participants must be PAP intolerant or have refused PAP to enroll.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
